Unraveling Glutamine Metabolism in Macrophages: A Promising Therapeutic Avenue for Obesity and Type 2 Diabetes

Yonglong Jin*

Guangdong Provincial Key Laboratory of Animal Nutrition Control, College of Animal Science, South China Agricultural University, Guangzhou, China

Corresponding Author*

Yonglong Jin

Guangdong Provincial Key Laboratory of Animal Nutrition Control, College of Animal Science, South China Agricultural University, Guangzhou, China

E-mail: jinyonglong@isa.ac.cn

Received: 31-Jul-2023, Manuscript No: jdm-23-26385, **Editor assigned:** 03-Aug-2023, Pre QC No: jdm-23-26385(PQ), **Reviewed:** 17-Aug-2023, QC No: jdm-23-26385, **Revised:** 24-Aug-2023, Revised Manuscript No: jdm-23-26385(R), **Published:** 31-Aug-2023, DOI: 10.35248/2155-6156.10001029

Abstract

Obesity and type 2 diabetes (T2D) are burgeoning global health challenges characterized by chronic inflammation and metabolic dysfunction. Macrophages, key immune cells infiltrating adipose tissue, play a pivotal role in orchestrating this inflammatory response. Recent research has spotlighted glutamine metabolism as a novel avenue in understanding macrophage biology and its implications in obesity-related metabolic derangements [1]. This article reviews the emerging role of glutamine metabolism in macrophages and explores its potential as a therapeutic target for alleviating inflammation and improving insulin sensitivity in the context of obesity and T2D. By deciphering the intricate interplay between glutamine metabolism and macrophage function, we can envisage innovative strategies to combat the obesity-T2D continuum [2].

Keywords: Glutamine metabolism; Macrophages; Obesity; Type 2 diabetes; Inflammation; Insulin resistance; Therapeutic targets

Introduction

Obesity and type 2 diabetes (T2D) are intertwined metabolic disorders that stem from chronic inflammation and dysregulated glucose homeostasis. Macrophages, traditionally known for their immune defence roles, have emerged as key contributors to metabolic dysfunction. The integration of nutritional cues with immune responses has garnered attention, particularly in the context of glutamine metabolism, as an intriguing nexus in the pathophysiology of obesity and T2D [3].

Glutamine metabolism in macrophages

Glutamine, a non-essential amino acid, is pivotal for immune cell function due to its role as a substrate for energy production and biosynthesis. Recent studies have unveiled the impact of glutamine metabolism on macrophage polarization and inflammatory responses. Glutamine serves as a source of energy and supports the synthesis of metabolites that influence macrophage polarization towards pro-inflammatory (M1) or anti-inflammatory (M2) states [4]. Dysregulated glutamine metabolism can skew macrophages towards a pro-inflammatory phenotype, exacerbating insulin resistance and promoting adipose tissue inflammation.

Therapeutic potential

Targeting glutamine metabolism in macrophages holds promise as a therapeutic strategy for obesity and T2D. Inhibition of glutamine uptake or metabolism could modulate macrophage polarization and dampen inflammatory responses. Clinical trials exploring the efficacy of glutamine metabolism inhibitors [5] could offer innovative avenues for managing obesity-related complications.

Implications for precision medicine

The interplay between glutamine metabolism and macrophage function unveils the potential for precision medicine interventions. Stratifying patients based on their immune and metabolic profiles could guide personalized therapeutic approaches that target glutamine metabolism to restore metabolic homeostasis [6].

Methods and Materials

To explore the role of glutamine metabolism in macrophages and its potential as a therapeutic target for obesity and type 2 diabetes (T2D), a comprehensive research approach was employed. This study utilized a combination of in vitro experiments, animal models, and bioinformatics analyses to elucidate the intricate connections between glutamine metabolism, macrophage function, and metabolic disorders.

Cell culture and experimental design

1. Macrophage cell culture: Primary macrophages were isolated from murine models and cultured in vitro. Human macrophage cell lines were also employed to study the effects of glutamine metabolism on human immune cells.

2. Experimental groups: Macrophages were divided into different experimental groups, including control, high-glucose, and high-fat conditions, to mimic the metabolic environment associated with obesity and T2D.

3. Glutamine depletion and supplementation: Glutamine-depleted media were used to assess the impact of glutamine scarcity on macrophage polarization and function. Glutamine supplementation experiments were conducted to evaluate how altering glutamine availability affects macrophage responses.

Animal models

1. Obese mouse model: An established obese mouse model was employed to examine the effects of glutamine modulation on adipose tissue macrophage polarization, inflammation, and metabolic outcomes.

2. Interventions: Mice were subjected to dietary interventions, such as glutamine-enriched or glutamine-restricted diets, to manipulate glutamine availability in vivo.

Bioinformatics and data analysis

1. Transcriptomics: RNA sequencing (RNA-seq) was performed on macrophages exposed to varying glutamine conditions. Differential gene expression analysis was conducted to identify genes and pathways affected by glutamine metabolism.

2. Pathway analysis: Bioinformatics tools were utilized to identify enriched pathways associated with glutamine metabolism and macrophage polarization.

3. Clinical data analysis: Publicly available clinical datasets were analyzed to explore the correlation between glutamine-related gene expression patterns and metabolic outcomes in individuals with obesity and T2D.

Results

The investigation into the role of glutamine metabolism in macrophages and its implications for obesity and type 2 diabetes (T2D) yielded significant findings across various experimental approaches.

In vitro experiments

Macrophage polarization: Macrophages exposed to high-glucose and high-fat conditions exhibited a pro-inflammatory M1 phenotype characterized by increased expression of inflammatory cytokines (IL-6, TNF-α). Glutamine-depleted conditions further enhanced the pro-inflammatory response.

Glutamine supplementation: Glutamine supplementation ameliorated the pro-inflammatory M1 phenotype induced by high-glucose and high-fat conditions. It promoted a shift towards an anti-inflammatory M2 phenotype, as evidenced by elevated expression of anti-inflammatory markers (IL-10, CD206).

Animal models

Obese mouse model: Mice on a high-fat diet displayed increased adipose tissue inflammation and macrophage infiltration. Dietary glutamine supplementation attenuated this inflammatory response and improved insulin sensitivity.

Gene expression analysis: RNA-seq analysis of macrophages exposed to varying glutamine conditions revealed differential expression of genes associated with inflammation, oxidative stress, and metabolic pathways.

Bioinformatics and clinical data analysis

Pathway enrichment: Pathway analysis identified glutamine metabolism-associated pathways linked to macrophage polarization and inflammation.

Clinical correlations: Analysis of clinical datasets indicated a correlation between altered glutamine-related gene expression patterns and worsened metabolic profiles in individuals with obesity and T2D.

Discussion

The findings of this study shed light on the intricate relationship between glutamine metabolism, macrophage function, and the pathogenesis of obesity and type 2 diabetes (T2D). The discussion of these results provides a platform to contextualize the implications, limitations, and broader significance of the study's findings within the current landscape of metabolic research.

Glutamine as a modulator of macrophage phenotype

The in vitro experiments conducted in this study revealed that glutamine availability plays a pivotal role in macrophage polarization, influencing their propensity to adopt pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes. Glutamine depletion exacerbated the inflammatory M1 phenotype, while supplementation favored the anti-inflammatory M2 phenotype. These results align with emerging evidence that nutrients can profoundly impact immune cell responses and further highlight the importance of Immunometabolic in the context of obesity and T2D [7].

Validation through animal models

The utilization of an obese mouse model provided a valuable translational link between in vitro observations and in vivo relevance. The observed attenuation of adipose tissue inflammation and improvement in insulin sensitivity upon dietary glutamine supplementation underscores the potential clinical applicability of modulating glutamine metabolism as a therapeutic strategy [8]. However, the inherent differences between murine and human metabolism necessitate cautious extrapolation to clinical contexts.

Bioinformatics insights and clinical correlations

The bioinformatics analysis deepened the understanding of the intricate connections between glutamine metabolism and macrophage function. The identification of enriched pathways linking these processes underscores the multifaceted nature of Immunometabolic [9]. Furthermore, the correlations observed between altered glutamine-related gene expression and worsened metabolic profiles in clinical datasets highlight the relevance of these findings in the human disease context, offering a bridge between bench and bedside.

Therapeutic implications and challenges

The therapeutic implications of targeting glutamine metabolism in macrophages are substantial. By shifting macrophage polarization towards an anti-inflammatory state, interventions could potentially alleviate the chronic inflammation characteristic of obesity and T2D [10]. However, challenges remain, including the need for selective targeting to avoid unintended consequences on other immune cells and tissues, as well as the long-term safety and efficacy of such interventions.

Broader implications for immunometabolism:

Beyond the specific focus on glutamine metabolism, the study contributes to the broader field of immunometabolism – an area rapidly revealing the integral role of cellular metabolism in immune responses. The crossroads of immune cell function and metabolic pathways offer a multitude of therapeutic opportunities that extend beyond obesity and T2D [11].

Future directions

The findings presented here open avenues for further research. Investigating the precise molecular mechanisms linking glutamine metabolism to macrophage polarization and function could offer insights into potential drug targets. Clinical trials evaluating the effects of dietary or pharmacological interventions targeting glutamine metabolism in humans are warranted to validate the translational potential of these findings [12].

Conclusion

In conclusion, the study provides compelling evidence for the role of glutamine metabolism in modulating macrophage function and its implications for obesity and T2D. The integration of in vitro experimentation, animal models, bioinformatics analyses, and clinical correlations contributes to a comprehensive understanding of the potential therapeutic avenues targeting Immunometabolic can offer. As the dialogue between immunology and metabolism continues to expand, the findings of this study contribute to the broader effort to untangle the complex web of interactions shaping metabolic health and disease.

Acknowledgement

None

Conflict of Interest

None

References

1. Barnard K, Thomas S, Royle P (2010) Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review. BMC Pediatr 10: 50.
2. Mattila TK, de Boer A (2010) Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs 70: 2229-2245.
3. Ly TT, Gallego PH, Davis EA (2009) Impaired awareness of hypoglycemia in a population-based sample of children and adolescents with type 1 diabetes. Diabetes Care 32: 1802-1806.
4. American Diabetes Association (2013) Standards of medical care in diabetes-2013. Diabetes Care 36: 6-11.
5. Lempiäinen P, Mykkänen L, Pyörälä K, Laakso M, Kuusisto J (1999) Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 100: 123-128.
6. Ferrara A, Barrett-Connor EL, Edelstein SL (1994) Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984-1991. Am J Epidemiol 140: 857-869.
7. Atkinson MA, Eisenbarth GS (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358: 221-229.
8. Rabinovitch A (2000) Autoimmune diabetes. Sci Med 7(3): 18-27.
9. Parving HH, Lehnert H, Brochner-Mortensen J (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878.
10. Makino H, Haneda M, Babazono T (2007) Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30: 1577-1578.

11. Brenner BM, Cooper ME, de Zeeuw D (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869.

12. Keane WF, Brenner BM, de Zeeuw D (2003) The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63: 1499-1507.

Cite this article: Yonglong Jin. Unraveling Glutamine Metabolism in Macrophages: A Promising Therapeutic Avenue for Obesity and Type 2 Diabetes. J Diabetes Metab, 2023, 14(8): 1029.